Efficacy News and Research

RSS

UI Cancer Center and GSU to help reduce cancer-related health disparities in Chicago's south suburbs

The greatest burden of cancer in the Chicago region has moved from the city to the suburbs. The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.

14 Oct 2015

Clinical study results of VolitionRx's NuQ test for pancreatic cancer published in Clinical Epigenetics

VolitionRx Limited today announced that full results from a completed clinical study of its NuQ blood-based test for early stage pancreatic cancers have been published in the online issue of Clinical Epigenetics, the official journal of the Clinical Epigenetics Society.

14 Oct 2015

XTL signs agreement with Yeda to amend development milestones for lupus treatment

XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, today announced that it has reached agreement with Yeda Research and Development Company Ltd. to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE).

13 Oct 2015

Phase III trial data shows Novartis’ Cosentyx maintains clear skin, sustained efficacy in psoriasis patients

Novartis announced today new late-breaking data demonstrating that CosentyxTM provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable safety profile across three years.

13 Oct 2015

Tamoxifen drug clears MRSA, reduces mortality

Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have found that the breast cancer drug tamoxifen gives white blood cells a boost, better enabling them to respond to, ensnare and kill bacteria in laboratory experiments. Tamoxifen treatment in mice also enhances clearance of the antibiotic-resistant bacterial pathogen MRSA and reduces mortality.

13 Oct 2015

Gensignia gets CLIA certification to establish clinical laboratory in San Diego

Gensignia Life Sciences, Inc. (Gensignia) announced today that it received certification under the Clinical Laboratory Improvement Amendments (CLIA).

13 Oct 2015

Lithium can be safe, effective for children suffering from bipolar disorder

A multicenter study of young patients with bipolar disorder provides what may be the most scientifically rigorous demonstration to date that lithium -- a drug used successfully for decades to treat adults with the condition -- can also be safe and effective for children suffering from it.

12 Oct 2015

Antiviral agent protects rhesus monkeys from deadly Ebola virus

Rhesus monkeys were completely protected from the deadly Ebola virus when treated three days after infection with a compound that blocks the virus's ability to replicate. These encouraging preclinical results suggest the compound, known as GS-5734, should be further developed as a potential treatment, according to research findings to be presented tomorrow at the IDWeek conference.

12 Oct 2015

UV robots help reduce rates of C. diff transmission among cancer inpatients

Robots are capable of all sorts of tasks to help better treat cancer: They connect oncologists to patients remotely, make incisions, staple them shut, deliver "nano" therapies--and they clean rooms. New research from Penn Medicine infection control specialists found that ultraviolet (UV) robots helped reduce the rates transmission of the common bacterial infection known as Clostridium difficile among cancer inpatients - mostly blood cancer patients, a group more vulnerable to hospital-acquired infections - by 25 percent. The interventions also saved about $150,000 in annual direct medical costs.

12 Oct 2015

ImmunArray launches SLE-key Rule-Out test for lupus patients

Following a limited three-month trial period in which more than one hundred and fifty patients with lupus-like symptoms were tested for the difficult-to-diagnose disease, a new blood test for lupus is being rolled out nationally.

12 Oct 2015

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

The U.S. Food and Drug Administration today approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other therapies.

9 Oct 2015

Hi-Tech Pharmaceuticals signs definitive agreement to acquire iForce

Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition products, Contract Manufacturing, and iForce Nutrition ("iForce"), one of the fastest-growing Sports Nutrition companies in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire iForce.

9 Oct 2015

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove the spleen.

9 Oct 2015

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks.

9 Oct 2015

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus.

9 Oct 2015

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy.

9 Oct 2015

Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults.

9 Oct 2015

Repatha (evolocumab) injection gets FDA approval for high cholesterol

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.

9 Oct 2015

BMC awarded NIDDK grant to study outcomes of minority women receiving diabetes self-management education

The National Institute of Diabetes and Digestive and Kidney Diseases has awarded a $783,906 grant to Suzanne Mitchell, MD, a family physician at Boston Medical Center, to study health outcomes of minority women with type 2 diabetes who participate in group medical visits to help them manage their diabetes.

9 Oct 2015

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

OncoGenex Pharmaceuticals, Inc. announced today that the European Medicines Agency has completed its review of the proposed amendment to the company's Phase 3 AFFINITY protocol and statistical analysis plan.

8 Oct 2015

Efficacy News and Research

UI Cancer Center and GSU to help reduce cancer-related health disparities in Chicago's south suburbs

Clinical study results of VolitionRx's NuQ test for pancreatic cancer published in Clinical Epigenetics

XTL signs agreement with Yeda to amend development milestones for lupus treatment

Phase III trial data shows Novartis’ Cosentyx maintains clear skin, sustained efficacy in psoriasis patients

Tamoxifen drug clears MRSA, reduces mortality

Gensignia gets CLIA certification to establish clinical laboratory in San Diego

Lithium can be safe, effective for children suffering from bipolar disorder

Antiviral agent protects rhesus monkeys from deadly Ebola virus

UV robots help reduce rates of C. diff transmission among cancer inpatients

ImmunArray launches SLE-key Rule-Out test for lupus patients

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

Hi-Tech Pharmaceuticals signs definitive agreement to acquire iForce

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

Repatha (evolocumab) injection gets FDA approval for high cholesterol

BMC awarded NIDDK grant to study outcomes of minority women receiving diabetes self-management education

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News